KRAS care partner and advocate Chris Conneran joined an international discussion on how artificial intelligence is shaping cancer care, with a focus on patient trust and transparency.

By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they

Expanded Access Can Feel Slow When Treatment Is Urgent. Each EAP has its own criteria for who may receive the drug. If the EAP is for pancreatic cancer, that does not mean it is available for other cancers unless those cancer types are specifically included in the EAP criteria. Every day counts, why does it take so long?

If weight holds steady or rises a little early in treatment, that can be an encouraging sign in lung cancer

Val’s Advice to Others Facing Lung Cancer ...a quiet but powerful advocate, offering guidance to other people, especially young adults with cancer: “Don’t freak out when you’re diagnosed. And don’t go straight to Google. Statistics don’t define you

Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type. 6 things that matter...

..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.